Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Y-mAbs Therapeutics Trading Up 2.8 %
NASDAQ:YMAB traded up $0.52 during trading hours on Friday, reaching $18.96. The company had a trading volume of 407,625 shares, compared to its average volume of 276,570. Y-mAbs Therapeutics has a 1-year low of $6.50 and a 1-year high of $39.82. The business's 50 day moving average price is $15.27 and its 200-day moving average price is $11.91.
Y-mAbs Therapeutics (NASDAQ:YMAB - Get Rating) last posted its quarterly earnings data on Monday, May 9th. The company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($0.71) by $0.07. The business had revenue of $10.49 million during the quarter, compared to analysts' expectations of $11.10 million. Y-mAbs Therapeutics had a negative return on equity of 59.67% and a negative net margin of 291.89%. The business's revenue was up 94.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.75 earnings per share. As a group, analysts forecast that Y-mAbs Therapeutics will post -1.7 EPS for the current year.
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on the company. BMO Capital Markets assumed coverage on Y-mAbs Therapeutics in a report on Thursday, June 23rd. They set an "outperform" rating and a $27.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and set a $63.00 target price on shares of Y-mAbs Therapeutics in a report on Friday, April 29th. Finally, Wedbush decreased their price target on Y-mAbs Therapeutics from $28.00 to $21.00 and set an "outperform" rating for the company in a report on Tuesday, May 10th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $30.83.